GREENWICH, Conn., Jan. 8, 2013 /CNW/ - Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that Aptuit and Aegerion Pharmaceuticals, Cambridge, Massachusetts, have signed a long-term supply agreement for commercial quantities of the active pharmaceutical ingredient (API) lomitapide.
(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )
Lomitapide is Aegerion's orphan drug that is targeted to the treatment of a rare disease caused by a genetic disorder. The drug received NDA approval in December of 2012 and is expected to be launched commercially in January of 2013. Previously, Aptuit scientists had established the chemistry for lomitapide, developed and validated its analytical methods, delivered solid state form control and crystallization R&D, and supplied registration batches of material. Post-launch, Aptuit will continue to supply commercial quantities of lomitapide to Aegerion.
Mr. Needleman explained, "Because of the drug's orphan status and high unmet medical need of the patients, on time and in full delivery of the API is crucial. Collaboration across several Aptuit sites in the US and Europe has made this possible. By accessing the vast drug development expertise of our organization, we have been able to accelerate the delivery of materials, methods, solid state chemistry and regulatory documentation and help the client win prompt NDA approval."
Although the exact terms of the agreement were not disclosed, Mr. Needleman added, "The collaboration represents another good example of how Aptuit's integrated, global drug development capabilities can have a direct, positive impact on the pharmaceutical industry."
Maria Garvey, Media Manager, Delfino Marketing, 914-747-1400
Jennifer Demaree, Senior Manager, Marketing & Communications, 203-660-6016
Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting and Aptuit INDiGO® (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy.
The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.
For more information about Aptuit, visit www.aptuit.com
SOURCE: Aptuit LLC
For further information:
PRN Photo Desk, firstname.lastname@example.org